Results 361 to 370 of about 3,006,723 (410)
The future of liquid biopsy [PDF]
The Lancet Oncology, 2020 The analysis of tumours using biomarkers in blood is beginning to transform cancer diagnosis, says Catherine Alix-Panabieres. The challenge now is to make liquid biopsy a standard clinical tool. The analysis of tumours using biomarkers in blood is beginning to transform cancer diagnosis, says Catherine Alix-Panabieres.
Jane Ganeshalingam +2 more
openaire +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2023
تم تطوير طرق جديدة للنظر في جينات الورم وديناميكياته: الخزعة السائلة (LB)، والتي تم دمجها في الممارسة السريرية كتحليل غير جراحي للمواد المتداولة المستمدة من الأورام، والتي تمثل أداة مبتكرة في علم الأورام الدقيق وتتغلب على القيود الحالية المرتبطة بخزعات الأنسجة. LB هي أداة جديدة ذات قيمة كبيرة، وتشكل علامة تشخيصية وتنبؤية وتنبؤية.
Alejandra Avagnina, María José Serrano
openaire +1 more source
تم تطوير طرق جديدة للنظر في جينات الورم وديناميكياته: الخزعة السائلة (LB)، والتي تم دمجها في الممارسة السريرية كتحليل غير جراحي للمواد المتداولة المستمدة من الأورام، والتي تمثل أداة مبتكرة في علم الأورام الدقيق وتتغلب على القيود الحالية المرتبطة بخزعات الأنسجة. LB هي أداة جديدة ذات قيمة كبيرة، وتشكل علامة تشخيصية وتنبؤية وتنبؤية.
Alejandra Avagnina, María José Serrano
openaire +1 more source
Genes, Chromosomes and Cancer, 2019
AbstractLiquid biopsy is based on minimally invasive blood tests and has a high potential to significantly change the therapeutic strategy in cancer patients, providing an extremely powerful and reliable noninvasive clinical tool for the individual molecular profiling of patients in real time.
Evi Lianidou, Klaus Pantel
openaire +2 more sources
AbstractLiquid biopsy is based on minimally invasive blood tests and has a high potential to significantly change the therapeutic strategy in cancer patients, providing an extremely powerful and reliable noninvasive clinical tool for the individual molecular profiling of patients in real time.
Evi Lianidou, Klaus Pantel
openaire +2 more sources
The potential of liquid biopsies
Current Opinion in Oncology, 2016This article discusses the current status and applications of liquid biopsy in nonsmall cell lung cancer (NSCLC).The discovery of genetic alterations which are responsible for the development and progression of NSCLC led to the identification of a new generation of molecular biomarkers.
Martin Filipits +2 more
openaire +2 more sources
Pathologists and liquid biopsies: to be or not to be?
Virchows Archiv, 2016Recently, the advent of therapies targeting genomic alterations has improved the care of patients with certain types of cancer. While molecular targets were initially detected in nucleic acid samples extracted from tumor tissue, detection of nucleic acids in circulating blood has allowed the development of what has become known as liquid biopsies ...
Helmut Popper, Paul Hofman
openaire +3 more sources
Liquid Biopsy Based on Cell-Free DNA and RNA.
Annual Review of Biomedical EngineeringThis review delves into the rapidly evolving landscape of liquid biopsy technologies based on cell-free DNA (cfDNA) and cell-free RNA (cfRNA) and their increasingly prominent role in precision medicine.
C. Loy +3 more
semanticscholar +1 more source
Acta Cytologica, 2018
The identification of non-small cell lung cancer (NSCLC) patients potentially responsive to targeted therapies relies on a number of relevant biomarkers, including <i>EGFR</i>, <i>ALK</i>, <i>ROS-1,</i> and PD-L1. Biomarker identification is most commonly based on surgical sample collection. However, when tissues are
Pisapia, Pasquale +2 more
openaire +4 more sources
The identification of non-small cell lung cancer (NSCLC) patients potentially responsive to targeted therapies relies on a number of relevant biomarkers, including <i>EGFR</i>, <i>ALK</i>, <i>ROS-1,</i> and PD-L1. Biomarker identification is most commonly based on surgical sample collection. However, when tissues are
Pisapia, Pasquale +2 more
openaire +4 more sources
Journal of biological regulators and homeostatic agents, 2019
During the early formation and growth of primary tumor (e.g., breast, colon, or prostate cancer), cells are shed from the primary tumor and then circulate through the bloodstream. Many of the major recent advances in targeted therapies have relied on the acquisition of tumor tissue via biopsy before initiation of therapy or after the onset of ...
Candotto, V +5 more
openaire +3 more sources
During the early formation and growth of primary tumor (e.g., breast, colon, or prostate cancer), cells are shed from the primary tumor and then circulate through the bloodstream. Many of the major recent advances in targeted therapies have relied on the acquisition of tumor tissue via biopsy before initiation of therapy or after the onset of ...
Candotto, V +5 more
openaire +3 more sources
The Cancer Journal, 2018
No two tumors are the same, and even within a single patient, the intratumor heterogeneity that exists contributes to the overall complexity in disease treatment and management. Yet, tumors are constantly shedding fragments into circulation with genetic material that help to fingerprint the tumor of origin.
Rhonda M. Jack, Sunitha Nagrath
openaire +3 more sources
No two tumors are the same, and even within a single patient, the intratumor heterogeneity that exists contributes to the overall complexity in disease treatment and management. Yet, tumors are constantly shedding fragments into circulation with genetic material that help to fingerprint the tumor of origin.
Rhonda M. Jack, Sunitha Nagrath
openaire +3 more sources
Liquid Biopsy: General Concepts
Acta Cytologica, 2019Liquid biopsy provides the opportunity of detecting, analyzing and monitoring cancer in various body effluents such as blood or urine instead of a fragment of cancer tissue. It is composed of different biological matrices such as circulating tumor cells (CTCs), cell free nucleic acids, exosomes or tumors “educated platelets.” In addition to ...
Poulet, Geoffroy +2 more
openaire +4 more sources